A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141.
Youn H. Kim
No relevant relationships to disclose
Michael Krathen
No relevant relationships to disclose
Madeleine Duvic
No relevant relationships to disclose
Henry Wong
No relevant relationships to disclose
Pierluigi Porcu
No relevant relationships to disclose
Joselin Tacastacas
No relevant relationships to disclose
Neil J Korman
No relevant relationships to disclose
Joan Guitart
No relevant relationships to disclose
James E. Bradner
Employment or Leadership Position - Shape Pharmaceuticals
Consultant or Advisory Role - Shape Pharmaceuticals
Stock Ownership - Shape Pharmaceuticals
Steven B. Landau
Employment or Leadership Position - Healthcare Ventures; Shape Pharmaceuticals
Stock Ownership - Shape Pharmaceuticals